Abstract

NACI recommends that AstraZeneca COVID-19 vaccine should not be used in adults under 55 years of age at this time while the safety signal of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following vaccination with AstraZeneca COVID-19 vaccine is investigated further.

  • Recommendation
  • Americas
  • Canada
  • Adults
  • Safety
  • AstraZeneca COVID-19 vaccine
  • COVID-19